Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery… (NCT06818006) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study)
Canada600 participantsStarted 2026-08-01
Plain-language summary
The purpose of this study is to see if having the Transcatheter Aortic Valve Replacement (TAVR) procedure done in a hospital with onsite cardiac surgery available or not, makes a difference on participant outcomes. Current standard of care is to have this procedure done in a hospital with onsite cardiac surgery available.
Hypothesis
The investigators hypothesize that the TAVR in experienced interventional cardiac centers without on-site cardiac surgery will be safe and effective. Although this is happening clinically in select regions internationally, this change in the clinical application of TAVI requires a rigorous assessment of safety with a robust randomized trial and multicenter international collaboration.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Severe symptomatic AS reviewed and accepted for Transfemoral (TF) TAVI by an established Heart Team
* Obtained informed consent
Exclusion Criteria:
* Ambiguous aortic annular sizing on CT measurement deemed to increase the risk of valve embolization
* Hostile aortic root on CT for TAVI implantation defined by, but not limited to:
* High risk LVOT with a dimension significantly smaller than the annulus and/or extensive calcification
* Features that increase the risk of coronary artery occlusion including inadequate coronary artery height and/or shallow coronary sinuses in the setting of a significant coronary artery territory at risk (accounting for prior CABG)
* High risk STJ anatomy defined by inadequate height and/or diameter and/or excessive calcification
* Vascular anatomy with increased risk of ascending aorta trauma (i.e. combinations of existing ascending aortic aneurysm, and/or unfolded aorta and/or extensive tortuosity and/or excessive iliofemoral calcification)
* GFR \<15, excluding patients on dialysis
* Life expectancy less than 3 years
* Any factor precluding 1-year follow-up
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Occurrence of an Emergent CardiacSurgery (ECS) event: Ventricular
Timeframe: From enrolment to the end of 90 day follow up
2
Death
Timeframe: From enrolment to the end of 90 day follow up
3
Myocardial Infarction
Timeframe: From enrolment to the end of 90 day follow up
4
Stroke
Timeframe: From enrolment to the end of 90 day follow up
5
Heart Failure Hospitalization
Timeframe: From enrolment to the end of 90 day follow up